Pharmafile Logo
Pharmafocus logo
Advanced Search

prostate cancer

Showing 15 posts of 85 posts found.

FDA approves Pfizer and Astellas Pharma’s prostate cancer drug

December 17, 2019
Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer

The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …

News
merck-keytruda

Prostate Cancer ‘super responders’ could live for two more years on Keytruda

November 28, 2019
Research and Development Cancer, immunotherapy, keytruda, oncology, prostate cancer

Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for …

News

Sanofi’s Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer

October 1, 2019
Manufacturing and Production, Research and Development ESMO 2019, Jevtana, Sanofi, pharma, prostate cancer

Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new …

News
janssen_latest_logo_on_sign_closer

FDA expands Janssen’s Erleada label to cover metastatic castration-sensitive prostate cancer

September 19, 2019
Sales and Marketing Cancer, Erleada, FDA, Janssen, pharma, prostate cancer

Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the …

News
astrazeneca_plaque

AstraZeneca’s Lynparza meets primary endpoint in Phase 3 prostate cancer trial

August 7, 2019
Research and Development Lynpraza, PARP inhibitor, lynparza, pharma, prostate cancer

AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic …

News
fda2outsideweb

Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer

July 31, 2019
Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer

The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …

News
8655563196_1c0f83c447_z

New urine test can diagnose and offer prognosis for prostate cancer

July 8, 2019
Sales and Marketing Cancer, oncology, pharma, prostate cancer, urine test

A new urine test can diagnose cases of aggressive prostate cancer more quickly than invasive biopsies. The test can also …

News
janssen_latest_logo_on_sign_closer

Janssen’s Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer

June 3, 2019
Research and Development, Sales and Marketing ASCO 2019, Cancer, Erleada, Janssen, prostate cancer

Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new …

News

Insider Interview: Paving paths in prostate cancer

May 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …

Feature

NICE turns down Astellas’ Xtandi in prostate cancer

April 8, 2019
Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer

Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …

News

Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer

February 18, 2019
Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer

Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …

News
janssen_latest_logo_on_sign

Janssen’s Erleada meets primary endpoints in ongoing trial into metastatic castration-sensitive prostate cancer

January 31, 2019
Research and Development Cancer, Erleada, Janssen, pharma, prostate cancer

Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been …

News
787px-prostate_normal_1

Prostate cancer researchers win $2m to explore carboplatin therapy

November 7, 2018
Research and Development Cancer, carboplatin therapy, prostate cancer

The US Department of Defence has awarded a coalition of researchers – made up of the Prostate Cancer Clinical Research …

News

FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer

July 16, 2018
Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer

Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …

News
shutterstock_349943306

Sophiris halts cancer study after patient death

June 25, 2018
Research and Development, Sales and Marketing Cancer, Sophiris, pharma, prostate cancer

Another clinical trial has been forced to a standstill as biotech firm Sophiris revealed that a patient death had prompted …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023